~~<i id='BFDFD0B8B9'><strike id='BFDFD0B8B9'><tt id='BFDFD0B8B9'><pre id='BFDFD0B8B9'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

Wikipedia

author：comprehensive 2025-09-02 08:19:41 - browse：1635

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： New study raises questions about niacin and heart health

entertainment

focus

knowledge

focus

leisure time

AdobeGroundbreakingresearchmorethanadecadeagoshowedthatalmostone-fifthofpeopleenrolledinMedicarewere

WSS

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Trans patients at the end of life deserve respect and dignity

Wegovy improves function in certain heart failure patients

Abridge raises $150m as clinical notes automation market heats up

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Listen: Vivek Ramaswamy's star turn & leaky drug data

entertainment

Wikipedia

entertainment

Drug repurposing or repositioning? The language matters

Republicans love RFK Jr. What's that tell us about health in 2024?

Medicare details structure of new drug price negotiation program

As AI regulations shape up, health tech startups beg for clarity

Heart attack and stroke risk calculators need revising

Wegovy improves function in certain heart failure patients

What does generative AI mean for health care? We asked experts

New study raises questions about niacin and heart health

Alkermes shareholders re

Listen: Vivek Ramaswamy's star turn & leaky drug data

focus

Elevance, SCAN deals highlight health insurer acquisition scrutiny

How the drug

Kellogg’s is going to war over Mexico’s nutrition label rules

California store owner shot dead in dispute over displaying Pride flag: Police

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

focus

knowledge

focus

leisure time